Literature DB >> 30087057

SPECT/CT-guided elective nodal irradiation for head and neck cancer: Estimation of clinical benefits using NTCP models.

Pieter D de Veij Mestdagh1, Tomas Janssen1, Emmy Lamers1, Casper Carbaat1, Olga Hamming-Vrieze1, Wouter V Vogel2, Jan-Jakob Sonke1, Abrahim Al-Mamgani3.   

Abstract

BACKGROUND AND
PURPOSE: The great majority of patients with lateralized head and neck squamous cell carcinoma (HNSCC) treated with radiotherapy routinely undergo bilateral elective nodal irradiation (ENI), even though the incidence of contralateral regional failure after unilateral ENI is low. Excluding the contralateral neck from elective irradiation could reduce radiation-related toxicity and improve quality-of-life. The current study investigated the dosimetric benefits of a novel approach using lymph drainage mapping by SPECT/CT to select patients for unilateral ENI. PATIENTS AND METHODS: Forty patients with lateralized cT1-3N0-2bM0 HNSCC underwent lymph drainage mapping. Two radiation plans were made; the real plan with which patients were actually treated (selective SPECT/CT-guided plan irradiating the ipsilateral neck ± any contralateral draining level); and the virtual plan (standard plan according to institutional guidelines, as if the same patient would have been treated bilaterally). Radiation doses to clinically important organs-at-risk were compared between the two plans. We used five normal tissue complication probability (NTCP) models to predict the clinical benefits of this approach.
RESULTS: Median dose reductions to the contralateral parotid gland, contralateral submandibular gland, glottic larynx, supraglottic larynx, constrictor muscle and thyroid gland were 19.2, 27.3, 11.4, 9.7, 12.1 and 18.4 Gy, respectively. Median NTCP reductions for xerostomia, contralateral parotid function, dysphagia, hypothyroidism and laryngeal edema were 20%, 14%, 10%, 20% and 5% respectively.
CONCLUSIONS: Selective SPECT/CT-guided ENI results in significant dose reductions to various organs-at-risk and corresponding NTCP values, and will subsequently reduce the incidence and severity of different troublesome radiation-related toxicities and improve quality-of-life.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Elective nodal irradiation; Head and neck cancer; Lymph drainage mapping; NTCP models; Radiotherapy; SPECT/CT

Mesh:

Year:  2018        PMID: 30087057     DOI: 10.1016/j.radonc.2018.07.023

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  4 in total

1.  Assessment of Occult Nodal Micrometastases to the Clinically Negative Contralateral Neck in Locally Advanced Supraglottic Squamous Cell Carcinoma.

Authors:  Ahmad Mohamed Eltelety; Mohamed Aly Abou-Zeid; Mena Esmat Abdelmalek; Ahmed Amin Nassar
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2021-08-17

2.  Incidence of contralateral regional failure in the electively irradiated contralateral neck of patients with head and neck squamous cell carcinoma.

Authors:  Pieter D de Veij Mestdagh; Eric van Werkhoven; Arash Navran; Jan Paul de Boer; Willem H Schreuder; Wouter V Vogel; Abrahim Al-Mamgani
Journal:  Clin Transl Radiat Oncol       Date:  2019-04-19

3.  Mapping of sentinel lymph node drainage using SPECT/CT to tailor elective nodal irradiation in head and neck cancer patients (SUSPECT-2): a single-center prospective trial.

Authors:  Pieter D de Veij Mestdagh; Willem H Schreuder; Wouter V Vogel; Maarten L Donswijk; Eric van Werkhoven; Jacqueline E van der Wal; Richard Dirven; Baris Karakullukcu; Jan-Jakob Sonke; Michiel W M van den Brekel; Corrie A M Marijnen; Abrahim Al-Mamgani
Journal:  BMC Cancer       Date:  2019-11-14       Impact factor: 4.430

4.  Characterizing Lymph Node Burden With Elective Unilateral Neck Irradiation in Human Papillomavirus-Positive Tonsil Squamous Cell Carcinoma: Defining the Upper Limits.

Authors:  Jared H Hara; Stanley I Gutiontov; Sophia Uddin; Ari J Rosenberg; Alexander T Pearson; Zhen Gooi; Elizabeth A Blair; Nishant Agrawal; Everett E Vokes; Daniel T Ginat; Daniel J Haraf; Aditya Juloori
Journal:  Cureus       Date:  2022-07-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.